Exane Derivatives Bei Gene, Ltd. Transaction History

Exane Derivatives

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 28, 2022	SELL	$248.56 - $389.34 $77,302 - $121,084	-311 Closed	0 $0
Q3 2021 Oct 26, 2021	BUY	$249.6 - $403.14 $17,971 - $29,026	72 Added 30.13%	311 $112,000
Q2 2021 Jul 28, 2021	SELL	$292.75 - $367.01 $36,886 - $46,243	-126 Reduced 34.52%	239 $82,000
Q1 2021 Apr 30, 2021	SELL	$260.64 - $382.12 $123,804 - $181,507	-475 Reduced 56.55%	365 $127,000
Q4 2020 Jan 27, 2021	BUY	$221.31 - $316.61 $17,704 - $25,328	80 Added 10.53%	840 $217,000
Q3 2020 Oct 06, 2020	BUY	$189.18 - $286.44 $1,891 - $2,864	10 Added 1.33%	760 $217,000
Q1 2020 Apr 17, 2020	BUY	$121.84 - $173.19 $91,380 - $129,892	750 New	750 $92,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

Stay updated on Exane Derivatives with notifications on news.